Sitemap   |  Contact  |  Home  |  中文  |  CAS
News & Events
  Upcoming Events
  Location:Home > News & Events > Upcoming Events
Direct Cellular Reprogramming in Tissue-Chip Development
Update time: 2017-07-25
Close Text Size: A A A Print

Speaker:Prof.Kam W. Leong

Sponsor:Prof.WANG Qiangbin

Time: 2:00p.m.Monday,July 31th


Bio:Kam W. Leong is the Samuel Y. Sheng Professor of Biomedical Engineering at Columbia University. He received his PhD in Chemical Engineering from the University of Pennsylvaf.nia. After serving as a faculty in the Department of Biomedical Engineering at The Johns Hopkins School of Medicine for almost 20 years, he moved to Duke University in 2006 to study the interactions of cells with nanostructures for therapeutic applications. After moving to Columbia University in September 2014, he continues to work on nanoparticle-mediated nonviral gene delivery and immunotherapy. The lab also works on the application of nanostructured biomaterials for regenerative medicine, particularly on understanding cell-topography interactions and on the application of nonviral vectors for direct cellular reprogramming and genome editing. He has published ~330 peer-reviewed research manuscripts with >35,000 citations, and holds more than 50 issued patents. His work has been recognized by a Young Investigator Research Achievement Award of the Controlled Release Society, Distinguished Scientist Award of the International Journal of Nanomedicine, Clemson Award for Applied Research of the Society for Biomaterials, and Life Time Achievement Award of the Chinese American Society of Nanomedicine and Nanotechnology. He is the Editor-in-Chief of Biomaterials, a member of the USA National Academy of Inventors, and a member of the USA National Academy of Engineering.

Abastract:Direct cell reprogramming or transdifferentiation, where adult cells are reprogrammed from one lineage to another without going through an intermediate stem cell-like stage, produces cells promising for regenerative medicine. It obviates the use of embryos and minimizes the risk of teratoma formation associated with the in vivo application of induced pluripotent stem cells. Direct reprogramming may offer advantages in tissue-chip development for disease modeling and drug screening because of savings in time and cost. I will discuss our recent effort to convert human endothelial progenitors (hEPC) into induced smooth muscle cells (iSMC), hEPC into induced skeletal myocytes (iSkM), human fibroblasts into induced cardiomyocyte-like cells (iSML), and murine fibroblasts into induced neurons (iN). I will describe various approaches of achieving direct cell reprogramming using transcription factor overexpression, microRNA delivery, molecular pathway manipulation, and CRISPR/dCas9-based transactivation either separately or in combination. This will be presented from the perspective of how biomaterials and biomedical engineering researchers can help advance this exciting field.

Copyright ©2008-2011 Suzhou Institute of Nano-Tech and Nano-Bionics (SINANO), CAS
Address: 398 Ruoshui Road, SEID, SIP, Suzhou, 215123, China|Tel:+86512 6287 2509|Fax:+86512 6260 3079|Email: